Atypical antipsychotics as a possible treatment option for irritable bowel syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pae, Chi-Un | - |
dc.contributor.author | Lee, Soo-Jung | - |
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Masand, Prakash S. | - |
dc.date.accessioned | 2021-09-06T01:47:01Z | - |
dc.date.available | 2021-09-06T01:47:01Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2013-05 | - |
dc.identifier.issn | 1354-3784 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/103292 | - |
dc.description.abstract | Introduction: Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder (FGID) that is characterised by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits. Although the pathophysiology of IBS is not fully understood, it is believed that psychiatric comorbidities are highly common in such patients. A variety of psychotropic medications are widely used in the treatment of IBS, particularly older antidepressants such as tricyclic antidepressants (TCAs). Areas covered: With the advent of newer antidepressant classes with better safety and tolerability compared with TCAs, such as serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), clinicians now have more advanced treatment options for treating IBS. Additionally, some atypical antipsychotics (AAs) have recently received approval for treatment of major depressive disorder (MDD). Some AAs may have potentials based on their pharmacodynamic profile and proven benefit for mood symptoms, pain, anxiety and sleep disturbances. This article describes the potential rationale, clinical data and practical aspects involved in the use of AAs for patients with IBS. Expert opinion: Atypical antipsychotics (AAs) may have a role in the treatment of irritable bowel syndrome (IBS) based on the currently available findings, although there is no clear evidence, and a number of clinical issues to be addressed in the use of AAs for the treatment of IBS. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject | FUNCTIONAL GASTROINTESTINAL DISORDERS | - |
dc.subject | SEROTONIN-TRANSPORTER | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | QUETIAPINE | - |
dc.subject | ANTAGONISTS | - |
dc.subject | OLANZAPINE | - |
dc.subject | MANAGEMENT | - |
dc.subject | EFFICACY | - |
dc.subject | SLEEP | - |
dc.subject | BRAIN | - |
dc.title | Atypical antipsychotics as a possible treatment option for irritable bowel syndrome | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.identifier.doi | 10.1517/13543784.2013.782392 | - |
dc.identifier.scopusid | 2-s2.0-84876255797 | - |
dc.identifier.wosid | 000317937800002 | - |
dc.identifier.bibliographicCitation | EXPERT OPINION ON INVESTIGATIONAL DRUGS, v.22, no.5, pp.565 - 572 | - |
dc.relation.isPartOf | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - |
dc.citation.title | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - |
dc.citation.volume | 22 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 565 | - |
dc.citation.endPage | 572 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | FUNCTIONAL GASTROINTESTINAL DISORDERS | - |
dc.subject.keywordPlus | SEROTONIN-TRANSPORTER | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | QUETIAPINE | - |
dc.subject.keywordPlus | ANTAGONISTS | - |
dc.subject.keywordPlus | OLANZAPINE | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SLEEP | - |
dc.subject.keywordPlus | BRAIN | - |
dc.subject.keywordAuthor | anxiety | - |
dc.subject.keywordAuthor | atypical antipsychotic | - |
dc.subject.keywordAuthor | depression | - |
dc.subject.keywordAuthor | irritable bowel syndrome | - |
dc.subject.keywordAuthor | neurotransmitter | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.